Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK
Pract Neurol. 2024 Jul 16;24(4):263-274. doi: 10.1136/pn-2023-004083.
Whole-genome sequencing (WGS) has recently become the first-line genetic investigation for many suspected genetic neurological disorders. While its diagnostic capabilities are innumerable, as with any test, it has its limitations. Clinicians should be aware of where WGS is extremely reliable (detecting single-nucleotide variants), where its reliability is much improved (detecting copy number variants and small repeat expansions) and where it may miss/misinterpret a variant (large repeat expansions, balanced structural variants or low heteroplasmy mitochondrial DNA variants). Bioinformatic technology and virtual gene panels are constantly evolving, and it is important to know what genes and what types of variant are being tested; the current National Health Service Genomic Medicine Service WGS offers more than early iterations of the 100 000 Genomes Project analysis. Close communication between clinician and laboratory, ideally through a multidisciplinary team meeting, is encouraged where there is diagnostic uncertainty.
全基因组测序(WGS)最近已成为许多疑似遗传性神经疾病的一线基因检测手段。虽然它的诊断能力是不可估量的,但和任何检测一样,它也有其局限性。临床医生应该了解 WGS 在哪些方面非常可靠(检测单核苷酸变异),在哪些方面可靠性大大提高(检测拷贝数变异和小重复扩展),以及在哪些方面可能会遗漏/误解变异(大片段重复扩展、平衡结构变异或低异质性线粒体 DNA 变异)。生物信息学技术和虚拟基因面板不断发展,了解正在检测的基因和变异类型非常重要;目前的英国国民保健署基因组医学服务的 WGS 提供的内容超过了早期的 10 万基因组计划分析。在存在诊断不确定性的情况下,鼓励临床医生和实验室之间进行密切沟通,理想情况下是通过多学科团队会议进行沟通。